Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Transcept Pharma Licenses Insomnia Treatment Candidate Intermezzo to Purdue Pharmaceutical

By Pharmaceutical Processing | August 3, 2009

NEW YORK (AP) — Shares of Transcept Pharmaceuticals Inc. rocketed Monday after the company said it licensed its insomnia treatment candidate Intermezzo to Purdue Pharmaceutical Products LP for up to $145 million, plus royalty payments. The agreement gives Purdue the exclusive right to sell the drug in the U.S. and negotiate for its approval in Canada and Mexico. Transcept retains the rights to the drug in all other countries, and it has the option to co-promote Intermezzo to psychiatrists in the U.S. In morning trading, shares of Richmond, Calif.-based Transcept jumped $3.75, or 64.7 percent, to $9.55. Earlier, they set a high of $10.49. The stock began trading in February and had ranged between $2.56 and $6.36. Intermezzo is intended to be taken in the middle of the night by people who wake up and then have difficulty getting back to sleep. Transcept said it could be the first prescription sleep aid approved for that purpose. The active ingredient in Intermezzo is zolpidem, which is also the main component of insomnia drugs like Ambien. Transcept said Intermezzo has only about one-third to one-quarter as much of the ingredient as other sleep aids. Under the agreement, Purdue will pay Transcept $25 million upfront, and up to $30 million more based on timing of approval by the Food and Drug Administration. Transcept could get up to $90 million more based on future milestones related to intellectual property and sales milestones. The deal also includes royalties of greater than 10 percent and as much as about 25 percent for Transcept. If Transcept exercises the psychiatric co-promotion option, it will receive an additional double-digit royalty on those sales. Transcept can begin co-promotion as soon as one year after launch. The FDA is scheduled to make a ruling on Intermezzo by Oct. 30.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE